Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Redwine12345on Oct 03, 2023 1:23pm
94 Views
Post# 35667259

RE:Settlement with Tylray

RE:Settlement with TylrayWell, to answer your concern, market already knew about 9m reward and it was built into the price already. So no surprise here. 
With respect to Tilray, from the other someone's post, I am sure that lawyers do know their business and they know how to sign the contracts. I am sure that they would calculate the bio-mass at today's price and the delivery would be in agreed bio-mass amount regardless of the future price of the bio-mass. I doubt that they would use fixed $ amount, unless the delivery is immediate.
Re 4.5m worth of shares in Tilray, I am sure they would use a fixed date and average share price to calculate the number of shares. You should be able to see the number of shares on LABS balance sheet when they release their financials. I guess, the price of the Tilray shares can go either way. 
Not the best option. Cash is better. However, building the relationship with the leader in industry is more important than stability of the cash. 
No comments on 500K other than, if this is the revenue, then there would be a margin that is less than 500K. In this case, the reward is less than 9m. I guess management is betting on share price appreciation and relationship more than on actual amount of settlement.  
<< Previous
Bullboard Posts
Next >>